

# OZEMPIC<sup>®</sup>

semaglutida

El nuevo tratamiento  
semanal con resultados  
superiores en pacientes  
con DMT2<sup>1-6</sup>



CONTROL  
GLICÉMICO  
SUPERIOR<sup>1-6</sup>

Novo Nordisk® Farmaceutica Limitada | Código CL20OZM00033



# PÉRDIDA DE PESO SUPERIOR Y SOSTENIDA<sup>1-6</sup>

Novo Nordisk® Farmaceutica Limitada | Código CL200ZM00033



BENEFICIOS  
CARDIOVASCULARES  
DEMOSTRADOS<sup>7</sup>

Novo Nordisk® Farmaceutica Limitada | Código CL200ZM00033

1. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. *Lancet Diabetes Endocrinol.* 2017 Apr;5(4):251-260. 2. Ahrén B et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. *Lancet Diabetes Endocrinol.* 2017 May; 5 (5): 341-354. 3. Ahman AJ et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. *Diabetes Care.* 2018 Feb; 41(2): 258-266. 4. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. *Lancet Diabetes Endocrinol.* 2017;5(5):355-366. 5. Rodbard HW et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. *J Clin Endocrinol Metab.* 2018 Jun 1;103(6):2291-2301. 6. Pratley RE, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. *Lancet Diabetes Endocrinol.* 2018 Apr;6(4):275-286. 7. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). *N Engl J Med* 2016; 375:1834-1844.



Material exclusivo para profesionales de la salud.  
El Folleto de información al profesional autorizado  
por ISP disponible escaneando el código QR.



Novo Nordisk® Farmaceutica Limitada | Código CL20OZM00033